iShares Global Clean Energy ETF vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? iShares Global Clean Energy ETF trades at $17.28 (market cap $2.27B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.6 (market cap $6.04B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 2.7× iShares Global Clean Energy ETF's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| ICLN | IOVA | |
|---|---|---|
Market Cap | $2.27B | $6.04B |
Volume | 6,845,064 | 14,805,993 |
52-Week High | $23.75 | $14.82 |
52-Week Low | $15.78 | $1.81 |
Typical Hold Time | 87 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $5.97B |
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.25, down 0.35% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 52.71 and 38.71. Recent news highlights ICLN's higher volatility and expense ratio compared to traditional energy ETFs, though geopolitical tensions and data center demand provide tailwinds for clean energy adoption.
The outlook remains challenged by competitive pressure from higher-yielding energy alternatives and significant historical drawdowns. However, global renewable energy acceleration and China's EV targets offer long-term growth potential. Key risks include fee structure disadvantages and sector volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →